Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
3 hedge funds and large institutions have $3.59M invested in Bristol-Myers Squibb Company Contingent Value Rights in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% more capital invested
Capital invested by funds: $3.59M → $3.59M ($0)
25% less funds holding
Funds holding: 4 → 3 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
Top Sellers
BMY.RT Hedge Fund Activity: Q1 2022 in Review
3 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q1 2022, worth a combined $3.59M — unchanged from a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BMY.RT and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
- 3 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q1 2022, down from 4 in Q4 2021.
- Funds reported $3.59M of Bristol-Myers Squibb Company Contingent Value Rights stock for Q1 2022, unchanged quarter-over-quarter.
- 1 fund opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q1 2022 and 2 closed out, a net change of -1 holder.
Based on aggregated 13F filings for Q1 2022.